Stuart Seigel, MD
Endocrinology, Diabetes & Metabolism · Laguna Niguel, CANPI 1073763983
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.2%), consulting fees and education — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Novo Nordisk at 46.1% of the total. Reporting peaked in 2020 at $2,130 and has fallen 97.1% since, to $62 in 2025.
Across 154 payments — averaging $32.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$416
- Abbott$396
- Corcept Therapeutics$395
- Dexcom, Inc.$307
- AstraZeneca$225
- plus $969 from 20 others
What the payments were for
- Consulting fees$1,89038%
- Food & beverage$2,97659%
- Education$1623%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $2,320 |
| Lilly USA, LLC | 30 | $416 |
| Abbott | 12 | $396 |
| Corcept Therapeutics | 6 | $395 |
| Dexcom, Inc. | 18 | $307 |
| AstraZeneca | 13 | $225 |
| Amgen(2 entities) | 12 | $212 |
| BETA Bionics, Inc. | 1 | $130 |
| Sanofi-aventis U.S. LLC | 5 | $80 |
| Mannkind Corporation | 4 | $69 |
| Bayer | 3 | $65 |
| Radius Health, Inc. | 3 | $58 |
| AbbVie | 4 | $55 |
| Tandem Diabetes Care, Inc. | 3 | $36 |
| Pfizer | 2 | $31 |
| Insulet Corporation | 2 | $30 |
| Medtronic(2 entities) | 2 | $29 |
| Boehringer Ingelheim | 1 | $27 |
| IBSA Pharma Inc. | 1 | $23 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Zealand Pharma US, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $19 |
| BD | 1 | $19 |
| Merck | 1 | $15 |
| Vivus LLC | 1 | $14 |
| Nalpropion Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$1,890
- iLet Bionic Pancreas$389
- Korlym$136
- Saxenda$121
How this compares
$5,027 in reported general payments places this provider in the 70th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 127 | $149,849 |
| MounjaroTirzepatide | 76 | $79,554 |
| JardianceEmpagliflozin | 77 | $77,861 |
| TrulicityDulaglutide | 33 | $34,357 |
| Humalog Kwikpen U-100Insulin Lispro | 87 | $20,352 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $15,508 |
| RybelsusSemaglutide | 13 | $14,081 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $13,998 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 35 | $13,877 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $13,547 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $9,699 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 86 | $8,518 |
| Novolog FlexpenInsulin Aspart | 20 | $4,509 |
| HumalogInsulin Lispro | 11 | $2,992 |
| Levothyroxine Sodium | 89 | $2,100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,320 | $163,930140 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $416 | $116,903120 claims |
| Boehringer IngelheimJardiance | $27 | $77,86177 claims |
| AbbVieSynthroid | $55 | $1,42520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Laguna Niguel
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.